Loading...

COVID‑19 Alert: Stay home if you feel unwell. If you have a fever, cough and difficulty breathing, seek medical attention. Follow the directions of your local health authority. Source WHO

We have a lockdown, "Working from HOME" Please reach out for any queries at: help@alliedmarketresearch.com & Int'l : +1-503-894-6022, (UK) : +44-845-528-1300

Premenstrual Syndrome Treatment Market by Drug Type (Analgesics, Antidepressants, Oral Contraceptives & Ovarian Suppression Agents, and Others), Type (Prescription and OTC), and Distribution Channel (Hospital Pharmacy, Drug Store & Retail Pharmacy, Online Providers): Global Opportunity Analysis and Industry Forecast, 2019–2026

A05965
Pages: 241
Jan 2020 | 964 Views
 
Author(s) : Sayali Shinde , Onkar Sumant
Tables: 116
Charts: 61
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Premenstrual Syndrome Treatment Market

Request Now !

The global Premenstrual Syndrome Treatment Market was valued at $1,129 million in 2018, and is projected to reach $1,516 million by 2026, registering a CAGR of 3.7% from 2019 to 2026. 

Premenstrual syndrome or PMS refers to physical & emotional symptoms, which occur one to two weeks before the initiation of woman's menses. It is characterized by symptoms such as acne, tender breasts, mood swings, bloating, fatigue, and irritability.  

The premenstrual syndrome treatment market is expected to experience a significant growth during the forecast period, owing to increase in awareness among patients, higher number of target population, rise in demand for PMS drugs, and easy availability of drugs. 

Premenstrual Syndrome Treatment Market

Get more information on this report : Request Sample Pages

For instance, according to the American Psychiatric Association, almost 90% of women of child bearing age experience premenstrual symptoms and less than 10% are diagnosed with premenstrual dysphoric disorder (PMDD). Thus, increase in prevalence of PMS is anticipated to fuel the demand for drugs, thereby driving the premenstrual syndrome treatment market growth. In addition, campaigns from government and non-government organizations to elevate female health status and education supports the market growth. However, unknown etiology and pathophysiology of PMS is anticipated to hamper the market growth. 

Premenstrual Syndrome Treatment Market Segmentation  

The global premenstrual syndrome treatment market is segmented on the basis of drug type, distribution channel, and region. By drug type, it is classified into analgesics, antidepressants, oral contraceptives & ovarian suppression agents, and others. Based on type it is classified as prescription and OTC.  According to distribution channel, the market is categorized as hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).   

Segment Review 

Based on drug type, the premenstrual syndrome treatment market is categorized into analgesics, antidepressants, oral contraceptives & ovarian suppression agents, and others. Presently, analgesics is the major revenue contributing segment, and is estimated to show a significant market growth during the forecast period due to higher adoption of analgesics as first line treatment for the management of PMS. 
Analgesics drugs such as ibuprofen, acetaminophen, diclofenac, naproxen are widely used in management symptoms of PMS. These analgesics are generally used to reduce PMS symptoms such as stomach cramps, headache, muscle pain, joint pain and others. These drugs are available over the counter without a prescription but their overuse may cause adverse effects. 

Premenstrual Syndrome Treatment Market
By Drug Type

Your browser does not support the canvas element.

Analgesics is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

According to distribution channel, the premenstrual syndrome treatment is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. The online providers segment is anticipated to depict significant growth during the forecast period, due to rise in preference for online purchasing of drugs over traditional methods, increase in awareness of online providers, and rise in number of internet users.

Premenstrual Syndrome Treatment Market
By Distribution Channel

Your browser does not support the canvas element.

Drug Store and Retail Pharmacy holds a dominant position in 2018 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Asia-Pacific Premenstrual Syndrome Treatment Market  

Asia-Pacific presents lucrative opportunities for the key players operating in the premenstrual syndrome treatment market, owing to the growth in awareness regarding premenstrual syndrome treatment, growth in healthcare awareness, and rise in adoption of premenstrual syndrome treatment products. Moreover, improvement in healthcare infrastructure, rise in number of target population, surge in healthcare reforms, and technological advancements in the field of healthcare further contribute to the market growth. Some other factors such as increase in focus of leading manufacturers on expanding their geographic presence in emerging Asia-Pacific countries to capture high growth opportunities in the market, due to high population base is expected to drive the growth of premenstrual syndrome treatment market in this region.  

Premenstrual Syndrome Treatment Market
By Geography

2026
North America 
Europe
Asia-pacific
Lamea

Asia-Pacific region would exhibit the highest CAGR of 5.1% during 2019-2026.

Get more information on this report : Request Sample Pages

The key players profiled in this report include ABBVIE INC., AstraZeneca plc., BASF Corporation, Bayer AG, Dr. Reddy’s Laboratories Ltd, Eli Lilly And Company, GlaxoSmithKline Plc., H. Lundbeck A/S, Pfizer Inc., and Shionogi Inc. 

Key Benefits for Stakeholders:

  • The study provides an in-depth analysis of the premenstrual syndrome treatment market size along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers the Premenstrual syndrome treatment market analysis from 2018 to 2026, which is expected to enable stakeholders to capitalize on the prevailing opportunities in the market.
  • A comprehensive analysis of all the four major geographical regions is provided to determine the prevailing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and global Premenstrual syndrome treatment market growth.

Key Market Segments:

By Drug Type 

  • Analgesics
  • Antidepressants
  • Oral Contraceptives & Ovarian Suppression Agents
  • Others

Type

  • Prescription
  • OTC 

By Distribution Channel 

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Providers  

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. Key findings

2.2.1. Top investment pockets
2.2.2. Top player positioning, 2018

2.3. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key forces shaping premenstrual syndrome treatment industry/market

3.2.1. Moderate power of suppliers
3.2.2. Moderate threat of new entrants
3.2.3. Low threat of substitution
3.2.4. Moderate competitive rivalry
3.2.5. Moderate bargaining power of buyers

3.3. Market dynamics

3.3.1. Drivers

3.3.1.1. Increase in prevalence of PMS
3.3.1.2. Growth in awareness for PMS therapeutics
3.3.1.3. Surge in healthcare expenditure worldwide

3.3.2. Restraint

3.3.2.1. Poor demand in under developed countries

3.3.3. Opportunities

3.3.3.1. Growth opportunities in emerging markets
3.3.3.2. Higher number of unmet needs for treatment of PMS

3.3.4. Impact analysis

CHAPTER 4: PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DRUG TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Analgesics

4.2.1. Key market trends and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country

4.3. Antidepressants

4.3.1. Key market trends and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country

4.4. Oral contraceptives & ovarian suppression agents

4.4.1. Key market trends and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country

4.5. Others

4.5.1. Key market trends and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country

CHAPTER 5: PREMENSTRUAL SYNDROME TREATMENT MARKET, BY TYPE.

5.1. Overview

5.1.1. Market size and forecast

5.2. Prescription

5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country

5.3. OTC

5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country

CHAPTER 6: PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL

6.1. Overview

6.1.1. Market size and forecast

6.2. Hospitals pharmacies

6.2.1. Market size and forecast
6.2.2. Market analysis, by country

6.3. Drug stores & retail pharmacies

6.3.1. Market size and forecast
6.3.2. Market analysis, by country

6.4. Online pharmacies

6.4.1. Market size and forecast
6.4.2. Market analysis, by country

CHAPTER 7: PREMENSTRUAL SYNDROME TREATMENT MARKET, BY REGION

7.1. Overview

7.1.1. Market size and forecast

7.2. North America

7.2.1. Key market trends, growth factors, and opportunities
7.2.2. Market size and forecast, by country

7.2.2.1. U.S.

7.2.2.1.1. U.S. premenstrual syndrome treatment market, by drug type
7.2.2.1.2. U.S. premenstrual syndrome treatment market, by type
7.2.2.1.3. U.S. premenstrual syndrome treatment market, by distribution channel

7.2.2.2. Canada

7.2.2.2.1. Canada premenstrual syndrome treatment market, by drug type
7.2.2.2.2. Canada premenstrual syndrome treatment market, by type
7.2.2.2.3. Canada premenstrual syndrome treatment market, by distribution channel

7.2.2.3. Mexico

7.2.2.3.1. Mexico premenstrual syndrome treatment market, by drug type
7.2.2.3.2. Mexico premenstrual syndrome treatment market, by type
7.2.2.3.3. Mexico premenstrual syndrome treatment market, by distribution channel

7.2.3. North America market size and forecast, by drug type
7.2.4. North America premenstrual syndrome treatment market, by type
7.2.5. North America premenstrual syndrome treatment market, by distribution channel

7.3. Europe

7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Market size and forecast, by country

7.3.2.1. Germany

7.3.2.1.1. Germany premenstrual syndrome treatment market, by drug type
7.3.2.1.2. Germany premenstrual syndrome treatment market, by type
7.3.2.1.3. Germany premenstrual syndrome treatment market, by distribution channel

7.3.2.2. France

7.3.2.2.1. France premenstrual syndrome treatment market, by drug type
7.3.2.2.2. France premenstrual syndrome treatment market, by type
7.3.2.2.3. France premenstrual syndrome treatment market, by distribution channel

7.3.2.3. UK

7.3.2.3.1. UK premenstrual syndrome treatment market, by drug type
7.3.2.3.2. UK premenstrual syndrome treatment market, by type
7.3.2.3.3. UK premenstrual syndrome treatment market, by distribution channel

7.3.2.4. Italy

7.3.2.4.1. Italy premenstrual syndrome treatment market, by drug type
7.3.2.4.2. Italy premenstrual syndrome treatment market, by type
7.3.2.4.3. Italy premenstrual syndrome treatment market, by distribution channel

7.3.2.5. Spain

7.3.2.5.1. Spain premenstrual syndrome treatment market, by drug type
7.3.2.5.2. Spain premenstrual syndrome treatment market, by type
7.3.2.5.3. Spain premenstrual syndrome treatment market, by distribution channel

7.3.2.6. Rest of Europe

7.3.2.6.1. Rest of Europe premenstrual syndrome treatment market, by drug type
7.3.2.6.2. Rest of Europe premenstrual syndrome treatment market, by type
7.3.2.6.3. Rest of Europe premenstrual syndrome treatment market, by distribution channel

7.3.3. Europe market size and forecast, by drug type
7.3.4. Europe premenstrual syndrome treatment market, by type
7.3.5. Europe premenstrual syndrome treatment market, by distribution channel

7.4. Asia-Pacific

7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Market size and forecast, by country

7.4.2.1. Japan

7.4.2.1.1. Japan premenstrual syndrome treatment market, by drug type
7.4.2.1.2. Japan premenstrual syndrome treatment market, by type
7.4.2.1.3. Japan premenstrual syndrome treatment market, by distribution channel

7.4.2.2. China

7.4.2.2.1. China premenstrual syndrome treatment market, by drug type
7.4.2.2.2. China premenstrual syndrome treatment market, by type
7.4.2.2.3. China premenstrual syndrome treatment market, by distribution channel

7.4.2.3. Australia

7.4.2.3.1. Australia premenstrual syndrome treatment market, by drug type
7.4.2.3.2. Australia premenstrual syndrome treatment market, by type
7.4.2.3.3. Australia premenstrual syndrome treatment market, by distribution channel

7.4.2.4. India

7.4.2.4.1. India premenstrual syndrome treatment market, by drug type
7.4.2.4.2. India premenstrual syndrome treatment market, by type
7.4.2.4.3. India premenstrual syndrome treatment market, by distribution channel

7.4.2.5. South Korea

7.4.2.5.1. South Korea premenstrual syndrome treatment market, by drug type
7.4.2.5.2. South Korea premenstrual syndrome treatment market, by type
7.4.2.5.3. South Korea premenstrual syndrome treatment market, by distribution channel

7.4.2.6. Rest of Asia-Pacific

7.4.2.6.1. Rest of Asia-Pacific premenstrual syndrome treatment market, by drug type
7.4.2.6.2. Rest of Asia-Pacific premenstrual syndrome treatment market, by type
7.4.2.6.3. Rest of Asia-Pacific premenstrual syndrome treatment market, by distribution channel

7.4.3. Asia-Pacific market size and forecast, by drug type
7.4.4. Asia-Pacific premenstrual syndrome treatment market, by type
7.4.5. Asia-Pacific premenstrual syndrome treatment market, by distribution channel

7.5. LAMEA

7.5.1. Key market trends, growth factors, and opportunities
7.5.2. Market size and forecast, by country

7.5.2.1. Brazil

7.5.2.1.1. Brazil premenstrual syndrome treatment market, by drug type
7.5.2.1.2. Brazil premenstrual syndrome treatment market, by type
7.5.2.1.3. Brazil premenstrual syndrome treatment market, by distribution channel

7.5.2.2. Saudi Arabia

7.5.2.2.1. Saudi Arabia premenstrual syndrome treatment market, by drug type
7.5.2.2.2. Saudi Arabia premenstrual syndrome treatment market, by type
7.5.2.2.3. Saudi Arabia premenstrual syndrome treatment market, by distribution channel

7.5.2.3. South Africa

7.5.2.3.1. South Africa premenstrual syndrome treatment market, by drug type
7.5.2.3.2. South Africa premenstrual syndrome treatment market, by type
7.5.2.3.3. South Africa premenstrual syndrome treatment market, by distribution channel

7.5.2.4. Rest of LAMEA

7.5.2.4.1. Rest of LAMEA premenstrual syndrome treatment market, by drug type
7.5.2.4.2. Rest of LAMEA premenstrual syndrome treatment market, by type
7.5.2.4.3. Rest of LAMEA premenstrual syndrome treatment market, by distribution channel

7.5.3. LAMEA market size and forecast, by drug type
7.5.4. LAMEA premenstrual syndrome treatment market, by type
7.5.5. LAMEA premenstrual syndrome treatment market, by distribution channel

CHAPTER 8: COMPANY PROFILES

8.1. ABBVIE INC.

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance

8.2. AstraZeneca plc

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments

8.3. BASF Corporation

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance

8.4. Bayer AG.

8.4.1. Company overview
8.4.2. Operating business segments
8.4.3. Product portfolio
8.4.4. Business performance

8.5. Dr. Reddy’s Laboratories Ltd

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance

8.6. Eli Lilly And Company.

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance

8.7. GlaxoSmithKline Plc.

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance

8.8. H. Lundbeck A/S

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance

8.9. Pfizer Inc.

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance

8.10. Shionogi Inc.

8.10.1. Company overview
8.10.2. Operating business segments
8.10.3. Product portfolio
8.10.4. Business performance

LIST OF TABLES

TABLE 01. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 02. ANALGESICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 03. ANTIDEPRESSANTS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 04. ORAL CONTRACEPTIVES & OVARIAN SUPPRESSION AGENTS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 05. OTHERS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 06. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026 ($MILLION)
TABLE 07. PRESCRIPTION PREMENSTRUAL SYNDROME TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 08. OTC PREMENSTRUAL SYNDROME TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 09. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026 ($MILLION)
TABLE 10. PREMENSTRUAL SYNDROME TREATMENT MARKET FOR HOSPITALS PHARMACIES, BY REGION, 2018–2026 ($MILLION)
TABLE 11. PREMENSTRUAL SYNDROME TREATMENT MARKET FOR DRUG STORES & RETAIL PHARMACIES, BY REGION, 2018–2026 ($MILLION)
TABLE 12. PREMENSTRUAL SYNDROME TREATMENT MARKET FOR ONLINE PHARMACIES, BY REGION, 2018–2026 ($MILLION)
TABLE 13. PREMENSTRUAL SYNDROME TREATMENT MARKET REVENUE, BY REGION, 2018–2026 ($MILLION)
TABLE 14. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 15. U.S. PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 16. U.S. PREMENSTRUAL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 17. U.S. PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 18. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 19. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 20. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 21. MEXICO PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 22. MEXICO PREMENSTRUAL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 23. MEXICO PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 24. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 25. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 26. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 27. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 28. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 29. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 30. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 31. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 32. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 33. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 34. UK PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 35. UK PREMENSTRUAL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 36. UK PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 37. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 38. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 39. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 40. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 41. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 42. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 43. REST OF EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 44. REST OF EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 45. REST OF EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 46. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 47. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 48. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 49. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 50. JAPAN PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 51. JAPAN PREMENSTRUAL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 52. JAPAN PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 53. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 54. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 55. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 56. AUSTRALIA PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 57. AUSTRALIA PREMENSTRUAL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 58. AUSTRALIA PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 59. INDIA PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 60. INDIA PREMENSTRUAL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 61. INDIA PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 62. SOUTH KOREA PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 63. SOUTH KOREA PREMENSTRUAL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 64. SOUTH KOREA PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 65. REST OF ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 66. REST OF ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 67. REST OF ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 68. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 69. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 70. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 71. LAMEA PREMENSTRUAL SYNDROME TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 72. BRAZIL PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 73. BRAZIL PREMENSTRUAL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 74. BRAZIL PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 75. SAUDI ARABIA PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 76. SAUDI ARABIA PREMENSTRUAL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 77. SAUDI ARABIA PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 78. SOUTH AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 79. SOUTH AFRIA PREMENSTRUAL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 80. SOUTH AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 81. REST OF LAMEA PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 82. REST OF LAMEA PREMENSTRUAL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 83. REST OF LAMEA PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 84. LAMEA PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 85. LAMEA PREMENSTRUAL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 86. LAMEA PREMENSTRUAL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 87. ABBVIE: COMPANY SNAPSHOT
TABLE 88. ABBVIE: OPERATING BUSINESS SEGMENTS
TABLE 89. ABBVIE: PRODUCT PORTFOLIO
TABLE 90. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 91. ASTRAZENECA: OPERATING BUSINESS SEGMENTS
TABLE 92. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 93. BASF: COMPANY SNAPSHOT
TABLE 94. BASF: OPERATING SEGMENTS
TABLE 95. BASF: PRODUCT PORTFOLIO
TABLE 96. BAYER.: COMPANY SNAPSHOT
TABLE 97. BAYER.: OPERATING SEGMENTS
TABLE 98. BAYER.: PRODUCT PORTFOLIO
TABLE 99. DR. REDDY’S: COMPANY SNAPSHOT
TABLE 100. DR. REDDY’S: OPERATING BUSINESS SEGMENTS
TABLE 101. DR. REDDY’S: PRODUCT PORTFOLIO
TABLE 102. LILLY: COMPANY SNAPSHOT
TABLE 103. LILLY: OPERATING SEGMENTS
TABLE 104. LILLY: PRODUCT PORTFOLIO
TABLE 105. GSK: COMPANY SNAPSHOT
TABLE 106. GSK: OPERATING BUSINESS SEGMENTS
TABLE 107. GSK: PRODUCT PORTFOLIO
TABLE 108. LUNDBECK: COMPANY SNAPSHOT
TABLE 109. LUNDBECK: OPERATING BUSINESS SEGMENTS
TABLE 110. LUNDBECK: PRODUCT PORTFOLIO
TABLE 111. PFIZER: COMPANY SNAPSHOT
TABLE 112. PFIZER: OPERATING SEGMENTS
TABLE 113. PFIZER: PRODUCT PORTFOLIO
TABLE 114. SHIONOGI: COMPANY SNAPSHOT
TABLE 115. SHIONOGI: OPERATING BUSINESS SEGMENTS
TABLE 116. SHIONOGI: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01. TOP INVESTMENT POCKETS
FIGURE 02. TOP PLAYER POSITIONING, 2018
FIGURE 03. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SEGMENTATION
FIGURE 04. IMPACT ANALYSIS
FIGURE 05. COMPARATIVE ANALYSIS OF ANALGESICS MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 06. COMPARATIVE ANALYSIS OF ANTIDEPRESSANTS MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 07. COMPARATIVE ANALYSIS OF ORAL CONTRACEPTIVES & OVARIAN SUPPRESSION AGENTS MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 08. COMPARATIVE ANALYSIS OF OTHERS MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 09. COMPARATIVE ANALYSIS OF PRESCRIPTION PREMENSTRUAL SYNDROME TREATMENT MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 10. COMPARATIVE ANALYSIS OF OTC PREMENSTRUAL SYNDROME TREATMENT MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 11. COMPARATIVE ANALYSIS OF PREMENSTRUAL SYNDROME TREATMENT MARKET FOR HOSPITALS PHARMACIES, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 12. COMPARATIVE ANALYSIS OF PREMENSTRUAL SYNDROME TREATMENT MARKET FOR DRUG STORES & RETAIL PHARMACIES, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 13. COMPARATIVE ANALYSIS OF PREMENSTRUAL SYNDROME TREATMENT MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 14. U.S. PREMENSTRUAL SYNDROME TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 15. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 16. MEXICO PREMENSTRUAL SYNDROME TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 17. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 18. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 19. UK PREMENSTRUAL SYNDROME TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 20. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 21. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 22. REST OF EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 23. JAPAN PREMENSTRUAL SYNDROME TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 24. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 25. AUSTRALIA PREMENSTRUAL SYNDROME TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 26. INDIA PREMENSTRUAL SYNDROME TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 27. SOUTH KOREA PREMENSTRUAL SYNDROME TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 28. REST OF ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 29. BRAZIL PREMENSTRUAL SYNDROME TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 30. SAUDI ARABIA PREMENSTRUAL SYNDROME TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 31. SOUTH AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 32. REST OF LAMEA PREMENSTRUAL SYNDROME TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 33. ABBVIE: NET SALES, 2016–2018 ($MILLION)
FIGURE 34. ABBVIE: REVENUE SHARE BY REGION, 2018(%)
FIGURE 35. ASTRAZENECA: NET SALES, 2016–2018 ($MILLION)
FIGURE 36. ASTRAZENECA: REVENUE SHARE BY REGION, 2018(%)
FIGURE 37. BASF: NET SALES, 2016–2018 ($MILLION)
FIGURE 38. BASF: REVENUE SHARE BY SEGMENT, 2018(%)
FIGURE 39. BASF: REVENUE SHARE BY REGION, 2018(%)
FIGURE 40. BAYER: NET SALES, 2016–2018 ($MILLION)
FIGURE 41. BAYER.: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 42. BAYER.: REVENUE SHARE BY REGION, 2018(%)
FIGURE 43. DR. REDDY’S: NET SALES, 2016–2018 ($MILLION)
FIGURE 44. DR. REDDY’S: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 45. DR. REDDY’S: REVENUE SHARE BY REGION, 2018(%)
FIGURE 46. LILLY: NET SALES, 2016–2018 ($MILLION)
FIGURE 47. LILLY: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 48. LILLY: REVENUE SHARE BY REGION, 2018(%)
FIGURE 49. GSK: NET SALES, 2016–2018 ($MILLION)
FIGURE 50. GSK: REVENUE SHARE BY SEGMENT, 2018(%)
FIGURE 51. GSK: REVENUE SHARE BY REGION, 2018(%)
FIGURE 52. LUNDBECK: NET SALES, 2016–2018 ($MILLION)
FIGURE 53. LUNDBECK: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 54. LUNDBECK: REVENUE SHARE BY REGION, 2018(%)
FIGURE 55. PFIZER: NET SALES, 2016–2018 ($MILLION)
FIGURE 56. PFIZER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 57. PFIZER: REVENUE SHARE BY REGION, 2018(%)
FIGURE 58. SHIONOGI: NET SALES, 2016–2018 ($MILLION)
FIGURE 59. SHIONOGI: REVENUE SHARE BY REGION, 2018(%)
FIGURE 60. SANOFI: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 61. SANOFI: REVENUE SHARE BY REGION, 2018(%)

 
 

Different form of drug such as analgesics, antidepressants, oral contraceptives, and ovarian suppression agents are used in the management of PMS.  The adoption of premenstrual syndrome therapeutics is expected to increase due to rise in the number of target population across the world and growth in awareness about premenstrual syndrome treatment in developing countries.

Ride in prevalence of PMS, increase in popularity of drug therapy, and surge in awareness regarding premenstrual syndrome treatment significantly boost the growth of the market. In addition, easy availability of drugs and unhealthy lifestyle can further support the market growth. However, unknown etiology of the disease is anticipated to hamper the market growth.

North America is expected to remain dominant during the forecast period, due to higher adoption of premenstrual syndrome treatment products, increased number of target population, presence of advanced healthcare facilities, easy availability of drugs, and early detection of this disease with higher health awareness among the general population drives the market growth. In addition, Asia-Pacific is expected to offer lucrative growth opportunities for the key market players during the forecast period, owing to rise in number of PMS affected population and awareness related to PMS.

 

PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library,  T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

FREQUENTLY ASKED QUESTIONS?
 

A. The market value of global premenstrual syndrome treatment market was $523.8 million in 2018.

A. The forecast period is from 2019 to 2026.

A. The market value of global premenstrual syndrome treatment market in 2019 is $542.1 million.

A. The adoption of premenstrual syndrome treatment is expected to increase due to rise in awareness among the patient population, higher number of target population, rise in demand for PMS drugs and easy availability of the drugs significantly drives the market growth.

A. The base year calculated in the report is 2018.

A. Yes, AstraZeneca plc is profiled in the report.

A. Emerging countries of Asia-Pacific region are growing at a growth % of 5.1%. Japan, China, Australia, India, South Korea are expected grow at a CAGR of 5.0%, 6.1%, 4.2%, 5.7%, 4.5%, respectively.

A. The North America market held a major share in the premenstrual syndrome treatment market in 2018 and is expected to continue the trend in the forecasting period. This is attributed to higher prevalence of PMS, higher healthcare awareness, presence of well-developed healthcare infrastructure along with early detection of the disease, presence of trained medical professionals, and easy accessibility to the therapeutics are majorly driving the market growth in North Americ

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Premenstrual Syndrome Treatment Market

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,769
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8,995
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/m
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly.
    This title and over 12,000+ are available on the Avenue Library.  T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts